Active, not recruiting Ofatumumab Dose-finding in RRMS Patients
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: ofatumumab/placebo
Phases: Phase I / Phase II
Last Updated Date: May 20, 2010
Primary Completion Date: September 2010

Active, not recruiting Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL), Untreated
Interventions: Drug: chlorambucil, tablets; Drug: ofatumumab (GSK1841157) infusion
Phase: Phase III
Last Updated Date: August 25, 2011
Primary Completion Date: March 2013

Active, not recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia; Waldenstrom Macroglobulinaemia
Intervention: Biological: Ofatumumab
Phase: Phase II
Last Updated Date: August 11, 2011
Primary Completion Date: March 2013

Active, not recruiting Ofatumumab Retreatment and Maintenance Treatment in CLL Patients
Condition: B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
Phase: Phase II
Last Updated Date: July 21, 2011
Primary Completion Date: February 2012

Active, not recruiting Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Lenalidomide; Drug: Ofatumumab
Phase: Phase II
Last Updated Date: July 14, 2011
Primary Completion Date: November 2013

Active, not recruiting A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Drug: ofatumumab 100 mg, 1000 mg / vial
Phase: Phase II
Last Updated Date: April 21, 2011
Primary Completion Date: June 2011

Active, not recruiting Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: Bendamustine and Ofatumumab
Phase: Phase II
Last Updated Date: April 15, 2011
Primary Completion Date: July 2011

Active, not recruiting Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
Condition: Diffuse Large B Cell Lymphoma (DLBCL)
Intervention: Drug: Ofatumumab
Phase: Phase II
Last Updated Date: July 7, 2011
Primary Completion Date: May 2010